The FDA and the CDC are confident that the vaccine is safe and effective at preventing COVID-19. At this time, the available data suggests that the chance of developing a rare blood disorder – thrombosis with thrombocytopenia syndrome (TTS) – is very low, and the benefits of the vaccine outweigh the risks.
For women between the ages of 18 and 49, this adverse event is rare, occurring at a rate of about 7 per 1 million vaccinated women. For women 50 years and older and men of all ages, this adverse event is even more rare. Women younger than 50 should be aware that other COVID-19 vaccines are available where this risk has not been seen.
Patients who receive the Janssen vaccine should monitor for severe headache, abdominal pain, leg pain or shortness of breath for 2 weeks after administration.
If experiencing symptoms, patients should contact their healthcare provider.
The Janssen, Pfizer-BioNTech, and Moderna COVID-19 vaccines are offered in select CVS locations.
Find locations and schedule your appointment